Errata

Volume 41, No. 7, page 3589, Abstract, 12th line should read:

follow-up period from the initiation of PBT was 42.9 months.

Volume 41, No. 7, page 3589, Abstract, 14th line should read:

overall survival rates were 80.2%, 12.1% and 71.3%,

Volume 41, No. 7, page 3591, Results, Treatment outcomes paragraph, 2nd line should read:

the initiation of PBT was 42.9 months (range=3.6-102.6


Volume 41, No. 7, page 3591, Results, Treatment outcomes paragraph, 8th-11th lines should read:

interval (CI)=55.1-100%], 12.1% (95% CI=0-33.7%) and 71.3% (95% CI=43.7-98.9%), respectively. Median survival time was 67.1 months (95% CI=24.0-110.2 months) (Figure 2).

Volume 41, No. 7, page 3592, Discussion, 1st line should read:

In our study, the 3-year OS and LC rates were 71.3% and

Volume 41, No. 7, page 3592, Figure 2 should be replace with the following:



Volume 41, No. 8, page 3860, right column, 13-14th lines should read:

Casitas B-lineage Lymphoma (CBL R149Q). Next-generation sequencing was attempted in another patient but failed due to

Volume 41, No. 8, page 3864, Authors' Contributions, 4th line should read:

Sandhu, Angela Sanguino and Shifeng Mao. Drafting of the article:

Volume 41, No. 8, page 3917, the Authors' list and the affiliations should read:

DANIEL STELLER¹, RONJA SIMON¹, ROBERT VON BIALY¹, RALPH PRIES² and SAMER G. HAKIM¹

Departments of ¹Maxillofacial Surgery, and ²Otolaryngology, Head and Neck Surgery, University Hospital of Lübeck, Lübeck, Germany

Volume 41, No. 8, page 3960, Table V should be replaced with:

| Table V. Descriptive statistics of the quantitative variables prior to treatment with abiraterone acetate (base line). Statistical differences between |
|--|
| the patients with higher (group A) and lower (group B) survival rates. |

| | All (n=53) Median (range) | Group A (n=27) Median (range) | Group B (n=26) Median (range) | <i>p</i> -Value* |
|-----------------------------|------------------------------|----------------------------------|----------------------------------|------------------|
| Treatment duration (months) | 16 (3-78) | 32 (6-78) | 8.5 (3-16) | <i>p</i> <0.0001 |
| PSA 2 w (ng/ml) | 24.37 (0.87-257) | 25.22 (3.47-257) | 19.93 (0.87-250) | <i>p</i> >0.05 |
| PSA 1 m (ng/ml) | 17.96 (0.56-240) | 10.40 (0.81-128) | 22.01 (0.56-240) | <i>p</i> >0.05 |
| PSA 2 m (ng/ml) | 21.20 (0.19-329) | 20.21 (0.19-329) | 22.71 (0.48-246) | <i>p</i> >0.05 |
| PSA 3 m (ng/ml) | 11.88 (0.05-244) | 8.24 (0.05-102) | 13.48 (0.33-244) | <i>p</i> >0.05 |
| PSA 4 m (ng/ml) | 12.41 (0.16-274) | 14.00 (0.52-274) | 9.83 (0.16-208) | <i>p</i> >0.05 |
| PSA 5 m (ng/ml) | 21.61 (0.06-261) | 15.73 (0.06-261) | 43.63 (5.50-199) | <i>p</i> =0.0304 |
| PSA 6 m (ng/ml) | 16.88 (0.00-423) | 11.06 (0.00-423) | 47.40 (1.47-282) | <i>p</i> =0.0163 |
| AP 2 w (UI/l) | 89 (46-735) | 84.5 (46-317) | 96 (54-735) | <i>p</i> >0.05 |
| AP 1 m (UI/l) | 92 (49-361) | 83 (49-361) | 102.5 (55-340) | <i>p</i> >0.05 |
| AP 2 m (UI/l) | 97.5 (41-441) | 83 (46-441) | 98 (41-299) | <i>p</i> >0.05 |
| AP 3 m (UI/l) | 84.5 (41-559) | 58 (41-559) | 95 (54-363) | <i>p</i> >0.05 |
| AP 4 m (UI/l) | 92.5 (38-300) | 57 (38-130) | 95 (41-300) | <i>p</i> >0.05 |
| AP 5 m (UI/l) | 72 (44-196) | 56 (44-139) | 86 (54-196) | <i>p</i> =0.0180 |
| AP 6 m (UI/l) | 71 (35-306) | 56 (35-150) | 107 (42-306) | <i>p</i> =0.0055 |
| LDH 2 w (UI/l) | 191 (133-613) | 167 (133-613) | 210 (152-317) | p=0.0424 |
| LDH 1 m (UI/l) | 189 (122-347) | 187 (141-287) | 197 (122-347) | <i>p</i> >0.05 |
| LDH 2 m (UI/l) | 197 (137-393) | 185 (146-253) | 209 (137-393) | <i>p</i> >0.05 |
| LDH 3 m (UI/l) | 224 (152-360) | 225 (166-281) | 206 (152-360) | p>0.05 |
| LDH 4 m (UI/l) | 200 (130-328) | 208 (165-267) | 199 (130-328) | <i>p</i> >0.05 |
| LDH 5 m (UI/l) | 218 (177-320) | 208 (189-308) | 219 (177-320) | p>0.05 |
| LDH 6 m (UI/I) | 194 (119-525) | 196 (154-525) | 192 (119-408) | p>0.05 |

*Mann-Whitney U-test. Bold values indicate statistical significance.